|
業務類別
|
Biotechnology |
|
業務概覽
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
| 公司地址
| 852 Winter Street, Suite 250, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 857 271-2954 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.zenasbio.com |
| 員工數量
| 130 |
| Ms. Jennifer A. Fox |
Principal Accounting Officer, Chief Business Officer and Chief Financial Officer |
美元 500.00K |
28/04/2025 |
| Mr. Orlando Oliveira |
Chief Commercial Officer |
美元 199.63K |
28/04/2025 |
| Mr. Leon Oliver Moulder, Jr |
Chief Executive Officer and Chairman of the Board |
美元 429.92K |
28/04/2025 |
| Dr. Lisa von Moltke, M.D. |
Head of Research and Development and Chief Medical Officer |
-- |
28/04/2025 |
| Mr. Joseph Farmer |
President and Chief Operating Officer |
美元 500.00K |
28/04/2025 |
|
|
| Dr. John J. Orloff, M.D. |
Independent Director |
28/04/2025 |
| Dr. Hongbo Lu, PhD |
Independent Director |
28/04/2025 |
| Mr. Tomas Kiselak |
Independent Director |
28/04/2025 |
| Mr. Jake R. Nunn |
Independent Director |
28/04/2025 |
| Mr. Patrick G. Enright, M.B.A. |
Independent Director |
28/04/2025 |
| Mr. Leon Oliver Moulder, Jr |
Chief Executive Officer and Chairman of the Board |
28/04/2025 |
| Ms. Patricia L. Allen |
Independent Director |
28/04/2025 |
| Mr. James P. Boylan, M.B.A. |
Independent Director |
28/04/2025 |
|
|
|
|
